Predictors and impact of major Hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial

被引:324
作者
Feit, Frederick [1 ]
Voeltz, Michele D.
Attubato, Michael J.
Lincoff, A. Michael
Chew, Derek P.
Bittl, John A.
Topol, Eric J.
Manoukian, Steven V.
机构
[1] NYU, Sch Med, Dept Med, New York, NY 10011 USA
[2] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[3] Cleveland Clin Fdn, Dept Med, Cleveland, OH 44195 USA
[4] Flinders Univ S Australia, Dept Cardiovasc Med, Adelaide, SA 5001, Australia
[5] Munroe Reg Med Ctr, Ocala Heart Inst, Ocala, FL USA
[6] Scripps Clin, Div Cardiovasc Dis, La Jolla, CA USA
关键词
D O I
10.1016/j.amjcard.2007.06.026
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients undergoing percutaneous coronary intervention (PCI) have a significant risk of hemorrhagic complications. Predictors of major hemorrhage and its relation to mortality in PCI are not well defined. Baseline and periprocedural predictors of major hemorrhage and its impact on mortality in patients undergoing elective or urgent PCI randomly assigned to heparin plus planned glycoprotein IIb/IIIa inhibitor (GPI) versus bivalirudin plus provisional GPIs in the REPLACE-2 Trial were determined. Of 6,001 patients, 3.2% experienced a major hemorrhage. Independent baseline predictors of major hemorrhage included advanced age, female gender, impaired creatinine clearance, and anemia. Independent periprocedural predictors of major hemorrhage included treatment with heparin plus GPI, increased procedural duration, provisional use of GPI, increased time to sheath removal, length of intensive care unit stay, and use of an intra-aortic balloon pump (all p <0.05). Mortality rates were higher in patients with than without major hemorrhage at 30 days (5.1% vs 0.2%), 6 months (6.7% vs 1.0%), and 1 year (8.7% vs 1.9%; p <0.001 for all). Furthermore, major hemorrhage was an independent predictor of 1-year mortality (odds ratio 2.66, 95% confidence interval 1.44 to 4.92, p = 0.002). In conclusion, in patients undergoing elective or urgent PCI, major hemorrhage was an independent predictor of I-year mortality. A number of baseline and periprocedural factors independently predicted major hemorrhage, including treatment with heparin plus GPI. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1364 / 1369
页数:6
相关论文
共 22 条
  • [1] TREATMENT WITH BIVALIRUDIN (HIRULOG) AS COMPARED WITH HEPARIN DURING CORONARY ANGIOPLASTY FOR UNSTABLE OR POSTINFARCTION ANGINA
    BITTL, JA
    STRONY, J
    BRINKER, JA
    AHMED, WH
    MECKEL, CR
    CHAITMAN, BR
    MARAGANORE, J
    DEUTSCH, E
    ADELMAN, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (12) : 764 - 769
  • [2] Blanc B., 1968, WHO TECH REP SER, V405, P5
  • [3] Relationship between activated clotting time and ischemic or hemorrhagic complications - Analysis of 4 recent randomized clinical trials of percutaneous coronary intervention
    Brener, SJ
    Moliterno, DJ
    Lincoff, AM
    Steinhubl, SR
    Wolski, KE
    Topol, EJ
    [J]. CIRCULATION, 2004, 110 (08) : 994 - 998
  • [4] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY
    CALIFF, RM
    SHADOFF, N
    VALETT, N
    BATES, E
    GALEANA, A
    KNOPF, W
    SHAFTEL, J
    BENDER, MJ
    AVERSANO, T
    RAQUENO, J
    GURBEL, P
    COWFER, J
    COHEN, M
    CROSS, P
    BITTL, J
    EDDINGS, K
    TAYLOR, M
    DEROSA, K
    HATTEL, L
    COOPER, L
    ESHELMAN, B
    FINTEL, D
    NIEMYSKI, P
    KLEIN, L
    KENNEDY, H
    THORNTON, T
    KEREIAKES, D
    MARTIN, L
    ANDERSON, L
    HIGBY, N
    ELLIS, S
    BREZINA, K
    GEORGE, B
    CHAPEKIS, A
    SMITH, D
    ANWAR, A
    GERBER, TL
    PRITCHARD, GL
    MYLER, R
    SHAW, R
    MURPHY, M
    WARD, K
    MADIGAN, NP
    BLANKENSHIP, J
    HALBERT, M
    FLANAGAN, C
    TANNENBAUM, M
    POLICH, M
    STEVENSON, C
    TCHENG, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961
  • [5] Bivalirudin - A review of its potential place in the management of acute coronary syndromes
    Carswell, CI
    Ploskcr, GL
    [J]. DRUGS, 2002, 62 (05) : 841 - 870
  • [6] Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk
    Chew, DP
    Bhatt, DL
    Lincoff, AM
    Wolski, K
    Topol, EJ
    [J]. HEART, 2006, 92 (07) : 945 - 950
  • [7] Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention - Results from the REPLACE-2 trial
    Cohen, DJ
    Lincoff, AM
    Lavelle, TA
    Chen, HL
    Bakhai, A
    Berezin, RH
    Jackman, D
    Sarembock, IJ
    Topol, EJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (09) : 1792 - 1800
  • [8] HEPARIN NEUTRALIZATION BY PLATELET-RICH THROMBI - ROLE OF PLATELET FACTOR-4
    EITZMAN, DT
    CHI, L
    SAGGIN, L
    SCHWARTZ, RS
    LUCCHESI, BR
    FAY, WP
    [J]. CIRCULATION, 1994, 89 (04) : 1523 - 1529
  • [9] Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions
    Kinnaird, TD
    Stabile, E
    Mintz, GS
    Lee, CW
    Canos, DA
    Gevorkian, N
    Pinnow, EE
    Kent, KM
    Pichard, AD
    Satler, LF
    Weissman, NJ
    Lindsay, J
    Fuchs, S
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2003, 92 (08) : 930 - 935
  • [10] Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization - REPLACE-2 randomized trial
    Lincoff, AM
    Kleiman, NS
    Kereiakes, DJ
    Feit, F
    Bittl, JA
    Jackman, JD
    Sarembock, IJ
    Cohen, DJ
    Spriggs, D
    Ebrahimi, R
    Keren, G
    Carr, J
    Cohen, EA
    Betriu, A
    Desmet, W
    Rutsch, W
    Wilcox, RG
    de Feyter, PJ
    Vahanian, A
    Topol, EJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (06): : 696 - 703